KBC Group
MLYS icon

KBC Group’s Mineralys Therapeutics MLYS Stock Holding History

KBC Group’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$33K Buy
+1,233
New +$36.2K ﹤0.01% 1778

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

KBC Group's MLYS Position: Q1 2026 in Review

KBC Group opened a new position in Mineralys Therapeutics (MLYS) in Q1 2026: 1,233 shares worth $33K. The stake represents ﹤0.01% of the portfolio and ranks #1778 among its holdings.

214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • KBC Group held 1,233 shares of Mineralys Therapeutics worth $33K as of Q1 2026.
  • Mineralys Therapeutics was a new KBC Group position in Q1 2026.
  • Mineralys Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q1 2026, its #1778 holding.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.